La eficacia de metformina y exenatida en pacientes con síndrome de ovario poliquístico (SOP)
DOI:
https://doi.org/10.30827/ars.v64i2.27302Palabras clave:
Exenatida; Metformina; Metaanálisis; Síndrome del Ovario PoliquísticoResumen
Introducción: El Síndrome del Ovario Poliquístico (SOP) es un trastorno hormonal que afecta al 5-10% de las mujeres que se encuentran en edad reproductiva. este metanálisis tiene como objetivo evaluar la eficacia de la metformina y la exenatida, respectivamente, y comparar la eficacia de ambos fármacos utilizando el Índice de Masa Corporal (IMC), el colesterol de lipoproteínas de baja densidad (LDL-C), el colesterol de lipoproteínas de alta densidad (HDL-C) y los niveles de testosterona.
Método: En este estudio se consultaron Scopus, Science Direct, Oxford Journal, Wiley Online Library y Medline a través del motor de búsqueda PubMed. El análisis estadístico de los estudios incluidos se realizó mediante el software RevMan 5.4.
Resultados: Hubo 6 estudios incluidos en el análisis del estudio. Hubo una reducción significativa en el IMC de las pacientes con SOP con exenatida frente a metformina (diferencia de medias = 0,51; intervalo de confianza (IC) del 95 % = 0,07; 0,96; I 2 = 52 %; p = 0,02). También hubo una reducción significativa en el nivel de testosterona de los pacientes con SOP con exenatida frente a metformina (diferencia de medias = 0,15; intervalo de confianza (IC) del 95 % = 0,07; 0,22;I 2 = 0 %; p = 0,0002). No hubo efecto sobre la media de LDL-C y de HDL-C cuando se comparó entre metformina y exenatida. Este muestra que la exenatida es eficaz para reducir el IMC y los niveles de testosterona en pacientes con SOP.
Conclusiones: Hubo una reducción significativa en el IMC y los niveles de testosterona de los pacientes con SOP cuando se usó exenatida en comparación con metformina. Sin embargo, no hubo efecto sobre la media de los niveles de LDL-C y HDL-C de las pacientes con SOP.
Descargas
Citas
Zheng S, Zhang Y, Long T, et al. Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women. Obesity Med. 2017;7: 15–20. Doi: 10.1016/j.obmed.2017.06.003
Abdalla MA, Shah N, Deshmukh H, et al. Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol. 2022;96(3):371-394. doi:10.1111/cen.14623.
Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019 Aug 1;3(8):1545-1573. doi: 10.1210/js.2019-00078.
Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1-13. doi: 10.2147/CLEP.S37559.
Papalou O, Livadas S, Karachalios A, et al. White blood cells levels and PCOS: Direct and indirect relationship with obesity and insulin resistance, but not with hyperandogenemia. Hormones. 2015;14(1):91-100. doi: 10.14310/horm.2002.1563.
Liu X, Zhang Y, Zheng SY, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87(6):767-774. doi: 10.1111/cen.13454.
Köksal B, Yildiz, S, Ozgöcer T, Yildiz, A, Vardi N, & Barutcu Ö. Investigation of possible effects of exendin-4 during exposure to mild chronic stress on dehydroepiandrosterone-induced polycystic ovary syndrome in rats. Acta Facultatis Medicae Naissensis. 2020;37(1):34–47. doi:10.5937/afmnai2001034K
Tao X, Cai L, Chen L, Ge S, Deng X. Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats. J Ovarian Res. 2019;12(1):86. doi:10.1186/S13048-019-0555-8
Saslow LR, Aikens JE. Lifestyle Interventions for Polycystic Ovary Syndrome: Cross-Sectional Survey to Assess Women’s Treatment and Outcome Preferences. JMIR Form Res. 2020;4(9):e17126. doi:10.2196/17126
Tao T, Zhang Y, Zhu YC, et al. Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. J Clin Endocrinol Metab. 2021;106(3):E1420-E1432. doi:10.1210/CLINEM/DGAA692
Haidich AB. Meta-analysis in medical research. Hippokratia. 2010;14(Suppl 1):29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049418/
Xing C, Lv B, Zhao H, Wang D, Li X, He B. Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats. J Steroid Biochem Mol Biol. 2021;214:105992. doi:10.1016/j.jsbmb.2021.105992
Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ. Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chin Med J (Engl). 2021;134(23):2882. doi:10.1097/CM9.0000000000001712
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement. J Clin Epidemiol. 2021;134:178-189. doi:10.1016/j.jclinepi.2021.05.008
Patten RK, Boyle RA, Moholdt T, Kiel I, Hopkins WG, Harrison CL, Stepto NK. Exercise Interventions in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Front Physiol. 2020;11:606. doi:10.3389/fphys.2020.00606
Biondi-Zoccai G, Lotrionte M, Landoni G, Modena MG. The rough guide to systematic reviews and meta-analyses. HSR Proceedings in Intensive Care & Cardiovascular Anesthesia. 2011;3(3):161-173.
Hooijmans CR, Rovers MM, De Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43. doi: 10.1186/1471-2288-14-43.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane; 2021. Available from www.training.cochrane.org/handbook.
Greger HK, Hanem LGE, Østgård HF, Vanky E. Cognitive function in metformin exposed children, born to mothers with PCOS - follow-up of an RCT. BMC Pediatr. 2020;20(1):408. doi: 10.1186/S12887-020-1960-2.
Jaganmohan C, Vannan M, Ali A, Parasuraman S. Evaluation of clinical efficacy of metformin therapy in Polycystic Ovary Syndrome. J Young Pharm. 2017;9(2):277-279. doi: 10.5530/jyp.2017.9.54.
Jensterle M, Kravos NA, Ferjan S, Goricar K, Dolzan V, Janez A. Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. Endocr Connect. 2020;9(1):44-54. doi:10.1530/EC-19-0449
Kumar D, Seshadri K, Pandurangi M. Effect of Metformin-sustained Release Therapy on Low-density Lipoprotein Size and Adiponectin in the South Indian Women with Polycystic Ovary Syndrome. Indian J Endocrinol Metab. 2017;21(5):679-684. doi:10.4103/IJEM.IJEM_154_17
Yang PK, Hsu CY, Chen MJ, et al. The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab. 2018;103(3):890-899. doi:10.1210/jc.2017-01739
Al-Ruthia YS, Al-Mandeel H, AlSanawi H, Mansy W, AlGasem R, AlMutairi L. Ovulation induction by metformin among obese versus non-obese women with polycystic ovary syndrome. Saudi Pharm J. 2017;25(5):795-800.
Ou HT, Chen PC, Wu MH. Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome. J Formos Med Assoc. 2017;116(2):80-89. doi:10.1016/j.jfma.2016.02.001
Tiwari N, Pasrija S, Jain S. Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2019;234:149-154. doi: 10.1016/j.ejogrb.2018.12.021
Morgante G, Massaro MG, Scolaro V, et al. Metformin doses and body mass index: Clinical outcomes in insulin resistant polycystic ovary syndrome women. Eur Rev Med Pharmacol Sci. 2020;24(15):8136-8142. doi: 10.26355/eurrev_202008_22500
Sharma S, Mathur DK, Paliwal V, Bhargava P. Efficacy of metformin in the treatment of acne in women with polycystic ovarian syndrome: A newer approach to acne therapy. J Clin Aesthet Dermatol. 2019;12(5):34.
Heidari B, Lerman A, Lalia AZ, Lerman LO, Chang AY. Effect of metformin on microvascular endothelial function in polycystic ovary syndrome. Mayo Clin Proc. 2019;94(12):2455. doi: 10.1016/j.mayocp.2019.06.015
Dawson AJ, Sathyapalan T, Vince R, et al. The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2019;10:189. doi: 10.3389/fendo.2019.00189
Tang L, Yuan L, Yang G, Wang F, Fu M, Chen M, Liu D. Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients. Clin Endocrinol (Oxf). 2019;91(4):508-516. doi: 10.1111/cen.14056.
Zheng S, Liu E, Zhang Y, et al. Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome but can be increased by exenatide or metformin treatment. Endocr J. 2019;66(6):555-562. doi: 10.1507/endocrj.EJ18-0153.
Matsuzaki T, Tungalagsuvd A, Iwasa T, et al. Clinical outcome of various metformin treatments for women with polycystic ovary syndrome. Reprod Med Biol. 2017;16(2):179-187. doi: 10.1002/rmb2.12026.
Tao T, Wu P, Wang Y, Liu W. Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment. BMC Endocr Disord. 2018;18(1):2. doi: 10.1186/s12902-018-0243-5.
Khan AA, Begum W. Efficacy of Darchini in the management of polycystic ovarian syndrome: A randomized clinical study. J Herb Med. 2019;15:100228. doi: 10.1016/j.hermed.2018.11.005.
Nemati M, Nemati S, Taheri AM, Heidari B. Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome. J Gynecol Obstet Hum Reprod. 2017 ;46(7):579-585. doi: 10.1016/j.jogoh.2017.07.004.
Paredes Palma JC, López Byhen E, Ibáñez L, Balladares Macedo L, Paredes Palma C, Ramírez Velázquez C. Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: A pilot study. Rev Med Hosp Gen Mex. 2018;81(1):15-26. doi: 10.1016/J.HGMX.2017.03.001.
Yaylali A, Bakacak M, Bakacak Z. The efficacy of different insulin-sensitizing agents on treatment outcomes in patients with polycystic ovary syndrome who underwent in-vitro fertilization: A retrospective, record-based, comparative study. J Gynecol Obstet Hum Reprod. 2021;50(1):101945. doi: 10.1016/j.jogoh.2020.102006.
Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, Dapagliflozin, or Phentermine/ Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021;106(10):3019-3033. doi: 10.1210/clinem/dgab408.
Tagliaferri V, Romualdi D, Immediata V, et al. Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol (Oxf). 2017;86(5):725-730. doi: 10.1111/cen.13304.
Pedersen AJT, Stage TB, Glintborg D, Andersen M, Christensen MMH. The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. Basic Clin Pharmacol Toxicol. 2018;122(2):239-244. doi:10.1111/BCPT.12874
Javed Z, Papageorgiou M, Deshmukh H, et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clin Endocrinol. 2019;90(6):805-813. doi:10.1111/cen.13968
Alpañés M, Álvarez-Blasco F, Fernández-Durán E, et al. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. Eur J Endocrinol. 2017;177(5):399-408. doi:10.1530/EJE-17-0516
Qian H, Xu W, Cui L, et al. Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial. Trials. 2021;22(1). doi:10.1186/S13063-021-05770-Z
Elsersy MAME. Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial. J Obstet Gynaecol India. 2017;67(5):363. doi:10.1007/S13224-017-1022-3
Bahadur A, Arora H, Ravi AK, et al. Comparison of Clinical, Metabolic and Hormonal Effects of Metformin Versus Combined Therapy of Metformin With Myoinositol Plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial. Cureus. 2021;13(6):e15510. doi:10.7759/cureus.15510
Ashok Kumar M, Samuel Gideon George P, Dasari A, Shanmugasundaram P. A single-blinded randomized trial to evaluate the efficacy of N-acetyl cysteine over metformin in patients with polycystic ovarian syndrome. Drug Invention Today. 2018;10(2):241-243.
Behrangi E, Sadeghi S, Sadeghzadeh-Bazargan A, et al. The effect of metformin in the treatment of intractable and late onset acne: A comparison with oral isotretinoin. Iran J Dermatol. 2019;22(88):47-52.
Løvvik TS, Carlsen SM, Salvesen Ø, et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(4):256-266. doi:10.1016/S2213-8587(19)30002-6
Dragamestianos C, Messini CI, Antonakis PT, et al. The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome. Gynecol Obstet Invest. 2019;84(1):35-44. doi:10.1159/000491086
Elkind-Hirsch KE, Paterson MS, Seidemann EL, Gutowski HC. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot. Fertil Steril. 2017;107(1):253-60.e1. doi: 10.1016/j.fertnstert.2016.09.023.
Ganie MA, Rashid A, Sood M, et al. Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. Gynecol Endocrinol. 2020;36(4):308-312. doi: 10.1080/09513590.2019.1675044..
Rashid A, Ganie MA, Wani IA, et al. Differential Impact of Insulin Sensitizers vs Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study. Horm Metab Res. 2020;52(2):89-94. doi: 10.1055/a-1084-5441
Wang J, Ruan X, Jin F, Sun Y, Wang J. Effects of exenatide combined with clomifene citrate on insulin resistance and angiotensin II/Angiotensin-(1-7) in peripheral blood in patients with polycystic ovary syndrome. Biomed Res. 2017;28(19):8406-8411. doi: 10.4061/2017/3678352.
Atef MM, Abd-Ellatif RN, Emam MN, Abo El Gheit RE, Amer AI, Hafez YM. Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach (selenium in PCOS). Arch Biochem Biophys. 2019;671:245-254. doi: 10.1016/j.abb.2019.06.009.
Hong G, Wu H, Ma ST, Su Z. Catechins from oolong tea improve uterine defects by inhibiting STAT3 signaling in polycystic ovary syndrome mice. Chin Med. 2020;15(1). doi: 10.1186/S13020-020-00405-Y
Abizadeh M, Novin MG, Amidi F, Ziaei SA, Abdollahifar MA, Nazarian H. Potential of Auraptene in Improvement of Oocyte Maturation, Fertilization Rate, and Inflammation in Polycystic Ovary Syndrome Mouse Model. Reprod Sci. 2020;27(9):1742-1751. doi: 10.1007/s43032-020-00168-9
Alahmadi AA, Alahmadi BA, Wahman LF, El-Shitany NA. Chamomile flower extract ameliorates biochemical and histological kidney dysfunction associated with polycystic ovary syndrome. Saudi J Biol Sci. 2021;28(11):6158-6166. doi: 10.1016/J.SJBS.2021.06.066
Khaled N, El-Bahy ASA, Radwan R, Handoussa H, AbdelMaksoud S. Ocimum kilimandscharicum L. restores ovarian functions in letrozole-induced Polycystic Ovary Syndrome (PCOS) in rats: Comparison with metformin. Life Sci. 2019;232(2019):116640. doi: 10.1016/j.lfs.2019.116640
Patel R, Shah G. Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. Arch Med Res. 2018;49(3):154-163. doi: 10.1016/j.arcmed.2018.08.001
Qiu Z, Dong J, Xue C, et al. Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway. J Ethnopharmacol. 2020;250:111965. doi: 10.1016/j.jep.2019.111965
Shirooie S, Khaledi E, Dehpour AR, et al. The effect of dapsone in testosterone enanthate-induced polycystic ovary syndrome in rat. J Steroid Biochem Mol Biol. 2021 Jul;214:105977. doi: 10.1016/j.jsbmb.2021.105977.
Wang Qq, Guo Xc, Li L, Gao Zh, Ji M. Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy. J Cell Physiol. 2020;235(2):1339-1348. doi: 10.1002/jcp.29051.
Wu Y, Li P, Zhang D, Sun Y. Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway. Exp Ther Med. 2018;15(2):2120-2127. doi: 10.3892/etm.2017.5650.
Wang Q, Shang J, Zhang Y, Zhou W. Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19. Cell Cycle. 2019;18(19):2538-2549. doi: 10.1080/15384101.2019.1652036.
Alahmadi AA, Alzahrani AA, Ali SS, et al. Both Matricaria chamomilla and Metformin Extract Improved the Function and Histological Structure of Thyroid Gland in Polycystic Ovary Syndrome Rats through Antioxidant Mechanism. Biomolecules. 2020;10(1):88. doi: 10.3390/biom10010088.
Ebrahimi F, Rostami S, Nekoonam S, Rashidi Z, Sobhani A, Amidi F. The Effect of Astaxanthin and Metformin on Oxidative Stress in Granulosa Cells of BALB C Mouse Model of Polycystic Ovary Syndrome. Reprod Sci. 2021;28(10):2807–2815. doi: 10.1007/s43032-021-00577-4.
Zhang S, Tu H, Yao J, et al. Combined use of Diane-35 and metformin improves the ovulation in the PCOS rat model possibly via regulating glycolysis pathway. Reprod Biol Endocrinol. 2020;18(1). doi: 10.1186/S12958-020-00613-Z.
Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2020;113(1):197–204.
Rashid R, Mir SA, Kareem O, et al. Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwanese Journal of Obstetrics and Gynecology. 2022;61(1):40–50. doi: 10.1016/j.tjog.2021.11.009.
Zhang J, Xing C, He B. Sodium-glucose cotransporter-2 inhibitors for improving endocrine and metabolic profiles in overweight and obese individuals with polycystic ovary syndrome: a meta-analysis protocol. BMJ Open. 2022;12:e058260. doi: 10.1136/bmjopen-2021-058260
Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670-2678. doi: 10.1210/JC.2008-0115
Liu J, Hu Y, Xu Y, Jia Y, Miao L, Wang G. Comparison of exenatide and metformin monotherapy in overweight/obese patients with newly diagnosed type 2 diabetes. Int J Endocrinol. 2017;2017:9401606. doi: 10.1155/2017/9401606
Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122(1-3):42-52. doi: 10.1016/j.jsbmb.2009.12.010
Moran LJ, Lombard CB, Lim S, Noakes M, Teede HJ. Polycystic ovary syndrome and weight management. Womens Health (Lond). 2010;6(2):271-283. doi: 10.2217/WHE.09.89
Sam S. Obesity and Polycystic Ovary Syndrome. Obes Manag. 2007;3(2):69. doi:10.1089/obe.2007.0019
Zhu J, Chen Z, Feng W, Long S, Mo ZC. Sex hormone-binding globulin and polycystic ovary syndrome. Clin Chim Acta. 2019;499:142-148. doi:10.1016/j.cca.2019.09.010
Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci. 2022;23(8):4110. doi:10.3390/ijms23084110
Faber J, Fonseca LM. How sample size influences research outcomes. Dental Press J Orthod. 2014;19(4):27-29. doi:10.1590/2176-9451.19.4.027-029.EBO
Andrade C. Sample size and its importance in research. Indian J Psychol Med. 2020;42(1):102. doi:10.4103/IJPSYM.IJPSYM_504_19
Hackshaw A. Small studies: strengths and limitations. Eur Respir J. 2008;32(5):1141-1143. doi:10.1183/09031936.00136408
Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med. 2009;37(12):3114-3119. doi:10.1097/CCM.0b013e3181bc7bd5
Feely A, Wall-Wieler E, Roos LL, Lix LM. Effect of Study Duration and Outcome Measurement Frequency on Estimates of Change for Longitudinal Cohort Studies in Routinely Collected Administrative Data. Int J Popul Data Sci. 2020;5(1). doi:10.23889/ijpds.v5i1.1150
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Gul-e-Saba Chaudhry
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Los artículos que se publican en esta revista están sujetos a los siguientes términos en relación a los derechos patrimoniales o de explotación:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, la cual se distribuirá con una licencia Creative Commons BY-NC-SA 4.0 que permite a terceros reutilizar la obra siempre que se indique su autor, se cite la fuente original y no se haga un uso comercial de la misma.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la fuente original de su publicación.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en repositorios institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
